Corcept Therapeutics Incorporated
CORT
$115.70
$1.721.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 16.02% | 12.20% | 12.79% | 17.92% | 25.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.02% | 12.20% | 12.79% | 17.92% | 25.71% |
| Cost of Revenue | 20.81% | 25.18% | 25.00% | 43.91% | 44.28% |
| Gross Profit | 15.94% | 12.00% | 12.60% | 17.53% | 25.45% |
| SG&A Expenses | 58.25% | 59.96% | 60.08% | 64.63% | 63.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.24% | 35.28% | 33.30% | 39.39% | 39.20% |
| Operating Income | -93.72% | -107.41% | -67.41% | -54.42% | -20.62% |
| Income Before Tax | -79.11% | -91.09% | -58.84% | -46.79% | -15.74% |
| Income Tax Expenses | -287.17% | -1,758.69% | -263.63% | -171.76% | -131.27% |
| Earnings from Continuing Operations | -58.71% | -64.67% | -29.43% | -25.18% | 6.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.71% | -64.67% | -29.43% | -25.18% | 6.09% |
| EBIT | -93.72% | -107.41% | -67.41% | -54.42% | -20.62% |
| EBITDA | -91.84% | -105.87% | -66.50% | -53.61% | -19.83% |
| EPS Basic | -59.24% | -64.77% | -30.18% | -26.14% | 4.46% |
| Normalized Basic EPS | -79.43% | -90.96% | -59.24% | -47.39% | -16.88% |
| EPS Diluted | -62.65% | -69.68% | -33.60% | -30.55% | -0.44% |
| Normalized Diluted EPS | -84.22% | -96.19% | -61.33% | -50.43% | -20.47% |
| Average Basic Shares Outstanding | 0.44% | 0.37% | 0.61% | 0.89% | 1.18% |
| Average Diluted Shares Outstanding | -2.20% | 0.21% | 5.79% | 7.28% | 6.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |